RenovoRx Inc(RNXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RNXT RenovoRx Inc

Market Closed 07-24 16:00:00 EDT

0.8653

+0.0108

+1.26%

盘后0.8653

+0.00000.00%

19:15 EDT

High0.8758	Low0.8401	Vol148.23K
Open0.8633	D1 Closing0.8545	Amplitude4.18%
Mkt Cap38.98M	Tradable Cap34.50M	Total Shares45.05M
T/O126.99K	T/O Rate0.37%	Tradable Shares39.87M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RNXT","market":"US","secType":"STK","nameCN":"RenovoRx Inc","latestPrice":0.8653,"timestamp":1784923200000,"preClose":0.8545,"halted":0,"volume":148234,"hourTrading":{"tag":"盘后","latestPrice":0.8653,"preClose":0.8653,"latestTime":"19:15 EDT","volume":20,"amount":17.3812,"timestamp":1784934910991,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.012638970157987034,"floatShares":39870300,"shares":45052700,"eps":-0.331663,"marketStatus":"Market Closed","change":0.0108,"latestTime":"07-24 16:00:00 EDT","open":0.8633,"high":0.8758,"low":0.8401,"amount":126990.7040472,"amplitude":0.041779,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.331663,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1785139200000},"marketStatusCode":7,"adr":0,"listingDate":1629950400000,"exchange":"NASDAQ","adjPreClose":0.8545,"postHourTrading":{"tag":"盘后","latestPrice":0.8653,"preClose":0.8653,"latestTime":"19:15 EDT","volume":20,"amount":17.3812,"timestamp":1784934910991,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.61756874709542},"requestUrl":"/m/hq/s/RNXT","defaultTab":"news","newsList":[{"id":"2648683338","title":"RenovoRx Granted Extended Nasdaq Compliance Period Amid Listing Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2648683338","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648683338?lang=en_us&edition=fundamental","pubTime":"2026-07-02 21:31","pubTimestamp":1782999101,"startTime":"0","endTime":"0","summary":"The latest announcement is out from RenovoRx ( ($RNXT) ). On December 31, 2025, RenovoRx received a deficiency notice from Nasdaq stating that its ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/renovorx-granted-extended-nasdaq-compliance-period-amid-listing-risk?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/renovorx-granted-extended-nasdaq-compliance-period-amid-listing-risk?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNXT","BK4539","BK4139","NQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648072725","title":"Renovorx Wins NASDAQ Extension to Regain $1 Minimum Bid Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2648072725","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648072725?lang=en_us&edition=fundamental","pubTime":"2026-07-02 20:31","pubTimestamp":1782995500,"startTime":"0","endTime":"0","summary":"RenovoRx wins Nasdaq extension to regain $1 minimum bid complianceRenovoRx received a Nasdaq notice granting a second 180-day window to regain the $1 minimum bid price listing requirement.New complian","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDLXP8CV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNXT","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648794567","title":"RenovoRx Stockholders Approve Directors and Equity Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2648794567","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648794567?lang=en_us&edition=fundamental","pubTime":"2026-07-01 05:20","pubTimestamp":1782854411,"startTime":"0","endTime":"0","summary":"RenovoRx ( ($RNXT) ) just unveiled an announcement. On June 30, 2026, RenovoRx, Inc. held its 2026 annual meeting of stockholders, where approximat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/renovorx-stockholders-approve-directors-and-equity-plan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/renovorx-stockholders-approve-directors-and-equity-plan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EQR","BK4539","RNXT","BK4585","BK4588","BK4139","BK4215"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648562105","title":"Renovorx Holds Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2648562105","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648562105?lang=en_us&edition=fundamental","pubTime":"2026-07-01 04:56","pubTimestamp":1782852961,"startTime":"0","endTime":"0","summary":"RenovoRx holds annual shareholder meetingRenovoRx held its annual shareholder meeting on June 30, 2026.Shareholders selected six directors to serve one-year terms through the 2027 annual meeting.Inves","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL9S05hp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNXT","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642284905","title":"RenovoRx highlights case study on intra-arterial gemcitabine delivery via TAMP in pancreatic cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2642284905","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642284905?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:34","pubTimestamp":1781181286,"startTime":"0","endTime":"0","summary":"RenovoRx highlighted a newly published peer-reviewed case study on its TAMP platform using RenovoCath to deliver gemcitabine for locally advanced pancreatic cancer.Results have already been presented via publication in Radiology Case Reports, not flagged for a future medical meeting.The report showed the procedure was completed without complications, supporting feasibility of localized intra-arterial delivery versus standard IV chemotherapy.Imaging suggested disease control on conventional scans, while metabolic imaging indicated a treatment response, pointing to PET-CT as a better monitoring tool.The case also showed physicians could manage challenging anatomy during the same session, potentially widening the addressable patient pool for the approach.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shou","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL5qjDqj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","RNXT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642282816","title":"RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2642282816","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642282816?lang=en_us&edition=fundamental","pubTime":"2026-06-11 20:30","pubTimestamp":1781181000,"startTime":"0","endTime":"0","summary":"PET-CT imaging, Rather than CT Alone, Presented a Meaningful Reduction in Tumor Metabolic Activity After Treatment, Suggesting that PET May Help to Optimize Therapeutic Response Monitoring Following T","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/11/3310469/0/en/RenovoRx-Highlights-Peer-Reviewed-Publication-Supporting-Intra-Arterial-Gemcitabine-Delivery-Via-TAMP-in-Locally-Advanced-Pancreatic-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AEIS","FDG","LABU","IE00B7SZL793.SGD","BK4585","BK4539","IE00B19Z4B17.USD","RNXT","IE0031619046.USD","LU0757428866.USD","BK4588","IE00B66KJ199.SGD","BK4157","LU1815336091.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640157194","title":"RenovoRx CEO Shaun Bagai presents at iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640157194","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640157194?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:30","pubTimestamp":1780576259,"startTime":"0","endTime":"0","summary":"RenovoRx will present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 23-24, 2026.CEO Shaun Bagai is scheduled to present on June 23 at 12:30 p.m. ET.Presentation to highlight first-quarter 2026 revenue momentum for RenovoCath, with updates on the Phase III TIGeR-PaC pancreatic cancer trial.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief on June 04, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDLc9ss8j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","RNXT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640953407","title":"RenovoRx Is Maintained at Buy by Ascendiant Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2640953407","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640953407?lang=en_us&edition=fundamental","pubTime":"2026-06-01 18:35","pubTimestamp":1780310100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RNXT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 01, 2026 06:35 ET (10:35 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638969323","title":"RenovoRx says FDA grants orphan drug designation for oxaliplatin in pancreatic cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2638969323","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638969323?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:31","pubTimestamp":1779971504,"startTime":"0","endTime":"0","summary":"RenovoRx received FDA orphan drug designation for oxaliplatin to treat pancreatic cancer, supporting its RenovoCath-enabled intra-arterial delivery program.Status provides development incentives, including potential seven-year market exclusivity if approved.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDLb9mYvV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","SG9999014039.USD","SG9999014021.USD","LU0314104364.USD","BK4588","NDAQ","BK4585","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","BK4139","IE00BGHQF748.EUR","LU2210150020.SGD","LU2210149790.SGD","RNXT","BK4112","BK4539","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00B64PRP62.GBP","LU2095319765.USD","IE00BKPKM429.USD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638669319","title":"RenovoRx - Odd Provides Seven Years of Market Exclusivity Upon FDA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2638669319","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638669319?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:30","pubTimestamp":1779971401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nTUA6NV52X:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNXT","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638159693","title":"RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2638159693","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638159693?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:30","pubTimestamp":1779971401,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nTUA6NV52X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNXT","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638654399","title":"RenovoRx announces pharmacokinetic data using TAMP platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2638654399","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638654399?lang=en_us&edition=fundamental","pubTime":"2026-05-26 22:34","pubTimestamp":1779806067,"startTime":"0","endTime":"0","summary":"RenovoRx (RNXT) announced that an abstract from a pharmacokinetic and pharmacodynamic sub-study of its ongoing Phase III TIGeR-PaC clinical trial h...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/renovorx-announces-pharmacokinetic-data-using-tamp-platform-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/renovorx-announces-pharmacokinetic-data-using-tamp-platform-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNXT","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638951233","title":"RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2638951233","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638951233?lang=en_us&edition=fundamental","pubTime":"2026-05-26 20:30","pubTimestamp":1779798600,"startTime":"0","endTime":"0","summary":"Sub-Study from Ongoing Phase III TIGeR-PaC Clinical Trial Supports TAMP for Targeted Intra-Arterial Delivery of Gemcitabine, Demonstrating Potential to Increase Local Drug Potency and Reduce Systemic ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/26/3301084/0/en/RenovoRx-Announces-Promising-Pharmacokinetic-Data-Using-the-TAMP-Platform-Presented-at-the-2026-ASCO-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT","LABU","BK4588","PK","BK4218","BK4139","BK4539","BK4181","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637766323","title":"RenovoRx releases investor presentation outlining RenovoCath commercialization ramp and TAMP platform for targeted cancer drug delivery","url":"https://stock-news.laohu8.com/highlight/detail?id=2637766323","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637766323?lang=en_us&edition=fundamental","pubTime":"2026-05-24 04:50","pubTimestamp":1779569411,"startTime":"0","endTime":"0","summary":"RenovoRx releases investor presentation outlining RenovoCath commercialization ramp and TAMP platform for targeted cancer drug delivery. RenovoRx outlined a commercial ramp for its FDA-cleared RenovoCath drug-delivery catheter, citing 16 active US cancer centers and a pipeline of 32 additional centers in evaluation or onboarding as of May 6, 2026.Projected 2026 revenue of $3-4 million; targeted 36 active commercial cancer centers by year-end.Reported $1.1 million in RenovoCath revenue in 2025; recorded $563,000 in Q1 2026, more than half of the prior-year total.Highlighted a potential peak annual US revenue opportunity of about $400 million for RenovoCath as a standalone device; cited pricing benchmarks of $6,000-$8,500 per unit and 5-6 procedures per patient.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260523:nNDL9k4T41:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637096361","title":"RenovoRx Insider Makes Bold Move With Fresh Share Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2637096361","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637096361?lang=en_us&edition=fundamental","pubTime":"2026-05-22 10:13","pubTimestamp":1779416013,"startTime":"0","endTime":"0","summary":"New insider activity at RenovoRx ( ($RNXT) ) has taken place on May 21, 2026. RenovoRx’s Chief Financial Officer, Mark Voll, has increased his stak...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/renovorx-insider-makes-bold-move-with-fresh-share-purchase-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/renovorx-insider-makes-bold-move-with-fresh-share-purchase-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RNXT","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637380892","title":"RenovoRx CFO Mark Voll buys 25,000 shares valued at $19,690","url":"https://stock-news.laohu8.com/highlight/detail?id=2637380892","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637380892?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:01","pubTimestamp":1779361267,"startTime":"0","endTime":"0","summary":"RenovoRx CFO Mark Voll reported an open-market purchase of 25,000 common shares at USD 0.79 each.Directly held common shares rose to 142,380 following the transaction.An additional 97,200 common shares were reported as indirectly held through the Voll Family Trust.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 21, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL8hWCkV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"RenovoRx CFO Mark Voll buys 25,000 shares valued at $19,690","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636893443","title":"RenovoRx Earnings Call Signals Commercial Inflection","url":"https://stock-news.laohu8.com/highlight/detail?id=2636893443","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636893443?lang=en_us&edition=fundamental","pubTime":"2026-05-20 08:16","pubTimestamp":1779236183,"startTime":"0","endTime":"0","summary":"Renovorx, Inc. (($RNXT)) has held its Q1 earnings call. Read on for the main highlights of the call. RenovoRx’s latest earnings call struck an upbe...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/renovorx-earnings-call-signals-commercial-inflection?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/renovorx-earnings-call-signals-commercial-inflection?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNXT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636856203","title":"RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th","url":"https://stock-news.laohu8.com/highlight/detail?id=2636856203","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636856203?lang=en_us&edition=fundamental","pubTime":"2026-05-19 20:30","pubTimestamp":1779193800,"startTime":"0","endTime":"0","summary":"MOUNTAIN VIEW, Calif., May  19, 2026  (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and com","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/19/3297484/0/en/RenovoRx-to-Present-at-the-Alliance-Global-Partners-Virtual-Annual-Healthcare-Company-Showcase-on-May-20th.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4137","LU0128526141.USD","XBI","LABU","BK4585","BK4539","HCSG","LU0029874061.USD","RNXT","BK4581","BK4588","XLV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635203245","title":"Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Lineage Therap (LCTX) and RenovoRx (RNXT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635203245","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635203245?lang=en_us&edition=fundamental","pubTime":"2026-05-16 03:30","pubTimestamp":1778873420,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tenaya Therapeutics (TNYA), Lineage Therap (LCTX) an...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-tenaya-therapeutics-tnya-lineage-therap-lctx-and-renovorx-rnxt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-tenaya-therapeutics-tnya-lineage-therap-lctx-and-renovorx-rnxt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LABU","LCTX","BK4581","BK4139","TNYA","LU0128526141.USD","HCSG","LU0029874061.USD","BK4137","XLV","RNXT","BK4539","XBI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635865520","title":"RenovoRx (RNXT) Gets a Buy from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2635865520","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635865520?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:56","pubTimestamp":1778842619,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on RenovoRx, with a price target of $3.00. The ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/renovorx-rnxt-gets-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/renovorx-rnxt-gets-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","RNXT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.renovorx.com;renovorx.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.092},{"period":"3month","weight":0.0102},{"period":"6month","weight":-0.1311},{"period":"1year","weight":-0.3344},{"period":"ytd","weight":0.03}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0078},{"period":"3month","weight":0.035},{"period":"6month","weight":0.0721},{"period":"1year","weight":0.1647},{"period":"ytd","weight":0.0836}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.049533},{"month":2,"riseRate":0.6,"avgChangeRate":0.102207},{"month":3,"riseRate":0.2,"avgChangeRate":-0.093103},{"month":4,"riseRate":0,"avgChangeRate":-0.163527},{"month":5,"riseRate":0.6,"avgChangeRate":0.050959},{"month":6,"riseRate":0.6,"avgChangeRate":0.043263},{"month":7,"riseRate":0.2,"avgChangeRate":-0.05079},{"month":8,"riseRate":0.25,"avgChangeRate":-0.119414},{"month":9,"riseRate":0.4,"avgChangeRate":-0.050074},{"month":10,"riseRate":0,"avgChangeRate":-0.120676},{"month":11,"riseRate":0.6,"avgChangeRate":0.028303},{"month":12,"riseRate":0.6,"avgChangeRate":0.479671}],"exchange":"NASDAQ","name":"RenovoRx Inc","nameEN":"RenovoRx Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"RenovoRx Inc(RNXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest RenovoRx Inc(RNXT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"RenovoRx Inc,RNXT,RenovoRx Inc股票,RenovoRx Inc股票老虎,RenovoRx Inc股票老虎国际,RenovoRx Inc行情,RenovoRx Inc股票行情,RenovoRx Inc股价,RenovoRx Inc股市,RenovoRx Inc股票价格,RenovoRx Inc股票交易,RenovoRx Inc股票购买,RenovoRx Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"RenovoRx Inc(RNXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest RenovoRx Inc(RNXT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}